ArticleCureus2025
Impaired Human Papillomavirus (HPV) Clearance in a Patient on Upadacitinib for Atopic Dermatitis: A Case of Refractory Genital Warts Resolved After Drug Withdrawal.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of refractory condyloma acuminatum in a young woman receiving upadacitinib for moderate-to-severe atopic dermatitis. The patient developed widespread genital and perianal warts while on upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor. Despite appropriate topical treatment with imiquimod, adjunctive cryotherapy, and herbal immunomodulatory agents, the lesions remained resistant to therapy. After consultation with the prescribing dermatologist, upadacitinib was discontinued while imiquimod was continued as monotherapy. Remarkably, within several weeks of drug cessation, the lesions regressed, and complete clinical resolution was observed within three months. No recurrence has been noted in the 10 months following clearance. This case underscores the potential for JAK1 inhibition to impair cellular antiviral immunity, particularly in the context of human papillomavirus (HPV)-related diseases such as condyloma acuminatum. The immunologic mechanism may involve suppression of interferon-γ, interleukin-2, and other cytokine pathways critical to viral clearance. Clinicians should be aware of this possible adverse interaction, especially when prescribing systemic immunomodulatory agents to sexually active patients or those with a history of HPV infection. Consideration of genital examination and prophylactic HPV vaccination prior to initiating JAK inhibitor therapy may be warranted. Furthermore, in cases of treatment-resistant genital warts, reassessing the patient's systemic immune status and current immunosuppressive medications may lead to improved clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.